

Background. Brucellosis is still endemic in many developing countries and frequently leads to misdiagnosis and treatment delays. Indirect inflammatory markers such as mean platelet volume (MPV), platelet distribution width (PDW), red cell distribution width (RDW), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been identified as markers of inflammation. The present study aimed to evaluate and compare the levels of these markers for prognostic purposes, and to assess the correlation of C-reactive protein (CRP) with brucellosis in adults and children.

Methods. The study included 137 adults and 141 age- and gender-matched healthy controls, as well 71 children and 81 age- and gender-matched healthy controls. Hematological parameters and CRP were retrospectively recorded and compared between the adult and pediatric patients.

Results. The mean age of the adult patients (54% female) was 43.1 ± 15.4 years, whereas the mean age of the pediatric patients (50.7% male) was 9.5 ± 3.6 years. Significantly higher lymphocyte count, and lower neutrophil count, platelet count, RDW, MPV, NLR and PLR values were found in adult brucellosis patients compared with their healthy subjects, whereas higher lymphocyte count, PDW and lower neutrophil count, platelet count, MPV, NLR and PLR values were observed in pediatric brucellosis patients compared with the control subjects. Significantly higher neutrophil count ($p = 0.019$) and NLR ($p < 0.001$) were found in adult patients compared with the pediatric patients. Positive correlation was found between CRP and NLR ($R^2 = 0.052$, $P = 0.011$), PLR ($R^2 = 0.061$, $P = 0.006$) in adult patients.

Conclusion. Based on our findings, we consider that the use of complementary indirect markers such as MPV, NLR, PLR and RDW together with the CRP test – which is used concomitantly with serological diagnostic tests in situations where brucellosis is suspected – might be helpful in the diagnosis and follow-up of brucellosis, as well as in the evaluation of complications and response to therapy, in both adult and pediatric brucellosis patients.

Disclosures. All authors: No reported disclosures.

1148. Impact of Procalcitonin (PCT)-Guided Antibiotic Therapy on Mortality in Critically Ill Patients: A Systematic Review and Meta-Analysis of 18 Randomized Controlled Trials

Dominique Pepper, MD MBChB¹; Junfeng Sun, PhD¹; Chanu Rhee, MD, MPH²; Judith Welsh, BSN³; John H. Powers III, MD⁴; Robert L. Danner, MD⁵ and Sameer Kadri, MD¹; ¹Critical Care Medicine Department, National Institutes of Health, Bethesda, MD, ²Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, ³National Institutes of Health Library, National Institutes of Health, Bethesda, Maryland, ⁴Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, ⁵Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland

Session: 144. Diagnostics: Biomarkers

Friday, October 6, 2017: 12:30 PM

Background. Procalcitonin (PCT)-guided antibiotic therapy has been shown to reduce antibiotic use in critically ill patients with suspected or proven infection, but its impact on mortality remains uncertain. Our meta-analysis examines the effect of PCT-guided antibiotic therapy on survival in critically ill patients.

Methods. We searched PubMed, the Cochrane Library, Scopus, Web of Science, EMBASE and clinicaltrials.gov electronic databases up to October 2016. The meta-analysis was restricted to randomized controlled trials (RCTs) of critically ill patients receiving PCT-guided antibiotic treatment and reporting survival or antibiotic duration. Study quality was assessed using the Cochrane risk of bias tool. Two reviewers conducted all review stages independently, and a third reviewer adjudicated any differences. Data was pooled using random-effects meta-analysis.

Results. Of the 18 RCTs selected ($n = 5,183$ patients; Table), 17 assessed mortality and 11 assessed antibiotic duration; 8 scored ≥ 3 and 10 scored ≤ 2 out of 6 on the risk of bias assessment. Compared with controls, PCT-guided antibiotic treatment was associated with a significant reduction in mortality (20.7% vs. 23.0%; risk ratio [RR] 0.90 [95% CI, 0.81–0.99], $I^2 = 0\%$; Figure 1). Survival benefit was retained in the RCT subset with a lower risk of bias (score ≥ 3 ; RR 0.87 [95% CI, 0.77, 0.98], $I^2 = 0\%$; Figure 2) but not with higher risk (score ≤ 2 ; RR 0.98 [95% CI, 0.80–1.20], $I^2 = 0\%$). Our analysis of the effect of PCT-guided antibiotic therapy on antibiotic duration displayed significant heterogeneity ($I^2 = 61.2\%$, $P = 0.004$), which precluded reporting on aggregate effect. Important limitations were: single center RCT ($n = 9$), lack of double blinding (all studies) and variable protocol non-adherence and timeframes examined for mortality.

Conclusion. In a meta-analysis of RCTs of critically ill patients with suspected or proven infection, PCT-guided antibiotic treatment was associated with a significant reduction in mortality. The observed survival benefit was weighted towards RCTs of relatively higher quality. However, the plausibility of this finding, as well as the impact of protocol non-adherence on outcome needs further study.

Funded by Intramural NIH and NCI Contract# HHSN261200800001E

Disclosures. All authors: No reported disclosures.

1149. Serial Procalcitonin Levels Correlate with Microbial Etiology in Hospitalized Patients with Pneumonia

Pierre Ankamah, MD, PhD¹; Suzanne McCluskey, MD²; Michael Abers, MD³; Benjamin Bearnot, MD²; Shreya Patel, MD, MPH⁴; Philipp Schuetz, MD, MPH⁵; Victor Chiappa, MD²; Kent Lewandowski, MD⁶; Jatin Vyas, MD, PhD, FIDSA⁷ and Michael Mansour, MD, PhD⁸; ¹Massachusetts General Hospital, Boston,

Massachusetts, ²Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, ³Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, ⁴UCSF, San Francisco, California, ⁵Medical University Clinic, Kantonsspital Aarau, Aarau, Switzerland, ⁶Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, ⁷Medicine; Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, ⁸Massachusetts General Hospital, Division of Infectious Diseases, Boston, Massachusetts

Session: 144. Diagnostics: Biomarkers

Friday, October 6, 2017: 12:30 PM

Background. Procalcitonin (PCT) is a biomarker that is finding increasing diagnostic and prognostic utility in lower respiratory infections. It remains unclear, however, whether it can be helpful in predicting the bacterial etiology of pneumonia, with a view to informing antibiotic choice and duration. This study examines the relationship between serial PCT measurements and microbial etiology in patients hospitalized for pneumonia to determine whether changes in PCT levels provide discriminatory information on microbial etiology.

Methods. We performed a subgroup analysis of data from a prospective cohort study of 505 patients admitted to a tertiary care center with findings concerning for pneumonia. Microbial etiology of pneumonia was determined from high quality respiratory samples, blood cultures or other relevant diagnostic tests according to standard protocols. Procalcitonin levels were measured serially during the first four days of hospitalization. We compared procalcitonin levels between different bacterial etiologies over the first four days of admission, using the Mann-Whitney-U test to assess for statistical significance.

Results. Out of 505 patients, the diagnosis of pneumonia was adjudicated in 317, and bacterial etiology determined in 62 cases. The predominant pathogens were *Staphylococcus aureus* ($N = 18$), *Streptococcus pneumoniae* ($N = 6$), *Pseudomonas aeruginosa* ($N = 11$) and *Haemophilus influenzae* ($N = 5$). Admission levels of PCT were lowest in *Pseudomonas* infections and highest in pneumococcal infections, though not reaching statistical significance. On hospital days two and three, pneumococcal procalcitonin levels were significantly higher than all other etiologies, but on day four, there was no statistically significant difference in PCT values for different microbial etiologies.

Conclusion. Serial procalcitonin levels during the early course of bacterial pneumonia reveal a difference between pneumococcal and other bacterial etiologies, and may have an adjunct role in guiding antibiotic choice and duration.

Disclosures. All authors: No reported disclosures.

1150. A Novel Host-protein Assay Accurately Distinguishes Bacterial From Viral Upper Respiratory Tract Infections

Kfir Oved, PhD¹; Eran Eden, PhD¹; Chantal Van Houten, MD²; Tanya Gottlieb, PhD³; Roy Navon, MSc¹; Asi Cohen, PhD¹; Olga Boico, PhD¹; Meital Paz, B.Sc.¹; Liat Etshtein, MD¹; Gali Kronenfeld, MSc¹; Tom Friedman, MD^{1,3}; Ellen Bamberger, MD^{1,4,5}; Irina Chistyakov, MD^{5,6}; Israel Potasman, MD, FIDSA⁷; Michal Stein, MD⁸; Adi Klein, MD⁹; Alain Gervais, MD¹⁰; Isaac Srugo, MD^{5,6} and Louis Bont, MD/PhD²; ¹MeMed Diagnostics, Tirat Carmel, Israel, ²Division of Pediatric Immunology and Infectious Diseases, University Medical Centre Utrecht, Utrecht, Netherlands, ³Rambam Health Care Campus, Haifa, Israel, ⁴Bnai Zion Medical Center, Haifa, Israel, ⁵Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, ⁶Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel, ⁷Infectious Diseases, Bnai Zion Med. Ctr., Haifa, Israel, ⁸Infectious Disease Unit, Hillel Yaffe Medical Center, Hadera, Israel, ⁹Department of Pediatrics, Hillel Yaffe Medical Center, Hadera, Israel, ¹⁰Pediatric Emergency Division, Geneva University Hospitals and University of Geneva, Geneva, Switzerland

Session: 144. Diagnostics: Biomarkers

Friday, October 6, 2017: 12:30 PM

Background. Bacterial and viral infections are often clinically indistinguishable, particularly in upper respiratory tract infections (URTI), which leads to antibiotic misuse. A novel assay (ImmunoXpert™) that integrates measurements of three host-response proteins (TRAIL, IP-10, CRP) was recently developed to assist in differentiation between bacterial and viral etiologies. We evaluated the assay performance in URTI patients and compared it with standard laboratory measures.

Methods. We performed a sub-analysis of 464 patients with clinical suspicion of URTI enrolled in three previously conducted multi-center clinical studies that evaluated the assay performance in patients with acute infections: 'Curiosity' study (NCT01917461), 'Opportunity' study (NCT01931254), and 'Pathfinder' study (NCT01911143). Comparator method was predetermined criteria combined with expert panel adjudication, which was blinded to the test results. Diagnostic performance was evaluated by comparing test and comparator method outcomes.

Results. A unanimous panel adjudication was attained for 61 bacterial (13%) and 241 viral (52%) patients (162 patients (35%) had an indeterminate diagnosis). The assay distinguished between bacterial and viral infected patients with a sensitivity of 92% (95% CI: 82%–98%) and specificity of 93% (88%–96%) with 11% equivocal test results. Overall the assay outperformed other routine laboratory tests (FIG 1), including: white blood cell count (WBC; cutoff 15,000 cells/ μ L, sensitivity 48% (35%–60%), $P < 10^{-6}$; specificity 85% (80%–90%), $P < 0.05$); CRP (cutoff 40 mg/L, sensitivity 82% (72%–92%), $P = 0.16$, specificity 79% (74%–84%), $P < 10^{-4}$); Procalcitonin (PCT; cutoff 0.5 ng/mL, sensitivity 22% (11%–32%), $P < 10^{-14}$, specificity 80% (74%–85%), $P < 0.001$); absolute neutrophil count (ANC; cutoff 10,000 cells/ μ L, sensitivity 58% (45%–71%), $P < 10^{-4}$, specificity 94% (91%–97%), $P = 0.7$).